Part 1—Cervical Screening in Australia 2000–2001

Part 1: Contents

List of table	es	4
List of figur	res	6
Acknowled	gments	7
Summary		8
National ce	rvical screening monitoring indicators	11
Participatio	n	15
Indicator 1:	Participation rate for cervical screening	17
Early re-scr	eening	20
Indicator 2:	Early re-screening	21
Low-grade	abnormalities	23
Indicator 3:	Low-grade abnormality detection	24
High-grade	abnormalities	25
Indicator 4:	High-grade abnormality detection	26
Incidence		29
Indicator 5:	Incidence of micro-invasive cervical cancer	30
Indicator 6:	Incidence of squamous, adenocarcinoma, adeno-squamous and other cervical cancers	32
Indicator 8:	Incidence by location	36
Mortality		39
Indicator 7:	Mortality	40
Indicator 9:	Mortality by location	43
Indicator 10	: Indigenous mortality	45
T-1-1		45

List of tables

Table 1:	Structure of the Rural, Remote and Metropolitan Areas classification	13
Table 1a:	Number of women participating in the National Cervical Screening Program by age, states and territories, 1999–2000	47
Table 1b:	Proportion of women participating in the National Cervical Screening Program by age, states and territories, 1999–2000	48
Table 2a:	Number of women participating in the National Cervical Screening Program by age, states and territories, 2000–2001	49
Table 2b:	Proportion of women participating in the National Cervical Screening Program by age, states and territories, 2000–2001	50
Table 3:	Number of women with repeat screenings in the 21 months following a negative Pap smear in February 2000, states and territories, 1999–2000 and 2000–2001	51
Table 4:	Percentage of women with repeat screenings in the 21 months following a negative Pap smear in February 2000, states and territories, 1999–2000 and 2000–2001	51
Table 5a:	Number of low- and high-grade abnormalities on histology for women aged 20–69 years, states and territories, 2000	52
Table 5b:	Number of low- and high-grade abnormalities on histology for women aged 20–69 years, states and territories, 2001	52
Table 6a:	Rate of histologically confirmed high-grade abnormalities per 1,000 women screened, states and territories, 2000	53
Table 6b:	Rate of histologically confirmed high-grade abnormalities per 1,000 women screened by age, states and territories, 2001	54
Table 7a:	Number of histologically confirmed high-grade abnormalities by age, states and territories, 2000	55
Table 7b:	Number of histologically confirmed high-grade abnormalities by age, states and territories, 2001	56
Table 8a:	Number of women screened by age, states and territories, 2000	57
Table 8b:	Number of women screened by age, states and territories, 2001	58
Table 9a:	Age-standardised high-grade abnormality rate on histology per 1,000 women screened aged 20–69 years, states and territories, 2000	59
Table 9b:	Age-standardised high-grade abnormality rate on histology per 1,000 women screened aged 20–69 years, states and territories, 2001	59
Table 10:	New cases of micro-invasive cervical cancer by age, Australia, 1989-2000	60
Table 11:	Age-specific and age-standardised rates of micro-invasive cervical cancer by age, Australia, 1989–2000.	61
Table 12:	New cases of cervical cancer by age, Australia, 1989-2000	62
Table 13:	Age-specific and age-standardised incidence rates of cervical cancer by	63

Table 14a:	New cases of cervical cancer by age, states and territories, 1996–1999	64
Table 14b:	Age-specific rates of cervical cancer, states and territories, 1996–1999	65
Table 15a:	Number of new cases of cervical cancer by age, states and territories, 1997–2000	66
Table 15b:	Age-specific rates of cervical cancer, states and territories, 1997–2000	67
Table 16a:	New cases of cervical cancer by histological type for women aged 20–69 years, Australia, 1989–2000.	68
Table 16b:	Age-standardised incidence rates for cervical cancer by histological type for women aged 20–69 years, Australia, 1989–2000	68
Table 17a:	New cases of cervical cancer by histological type for women, all ages, Australia, 1989–2000	69
Table 17b:	Age-standardised incidence rates for cervical cancer by histological type for women, all ages, Australia, 1989–2000	69
Table 18:	New cases of cervical cancer by age and location, 1993–1996 and 1997–2000	70
Table 19:	Age-specific and age-standardised incidence rates for cervical cancer by age and location, 1993–1996 and 1997–2000	71
Table 20:	Deaths from cervical cancer by age, Australia, 1982–2001	72
Table 21:	Age-specific and age-standardised death rates for cervical cancer by age, Australia, 1982–2001	73
Table 22:	Deaths from cervical cancer by age, states and territories, 1994–1997	74
Table 23:	Age-specific and age-standardised death rates for cervical cancer by age, states and territories, 1994–1997	75
Table 24:	Deaths from cervical cancer by age, states and territories, 1998–2001	76
Table 25:	Age-specific and age-standardised death rates for cervical cancer by age, states and territories, 1998–2001	77
Table 26:	Deaths from cervical cancer by age and location, 1994–1997 and 1998–2001	78
Table 27:	Age-specific and age-standardised death rates for cervical cancer by age and location, 1994–1997 and 1998–2001	79
Table 28:	Deaths from cervical cancer by age and Indigenous status, Queensland, South Australia, Western Australia and Northern Territory, 1996–1999, 1997–2000 and 1998–2001	80
Table 29:	Age-specific and age-standardised death rates for cervical cancer by age and Indigenous status, Queensland, South Australia, Western Australia and Northern Territory, 1996–1999, 1997–2000 and 1998–2001	81

List of figures

Figure 1:	Participation rates in the National Cervical Screening Program by age group, Australia, 1999–2000 and 2000–2001	17
Figure 2:	Participation (age-standardised) in the National Cervical Screening Program by women aged 20–69 years, states and territories, 1999–2000 and 2000–2001	19
Figure 3:	Proportion of women re-screened by number of screens during the 21-month period following a negative Pap smear in February 2000, Australia	21
Figure 4:	Proportion of women re-screened by number of screens during the 21-month period following a negative smear in February 2000, states and territories	22
Figure 5:	Ratio of low- to high-grade abnormalities by women aged 20–69 years, states and territories, 2000 and 2001	24
Figure 6:	High-grade abnormalities per 1,000 women by age group, Australia, 2000 and 2001	26
Figure 7:	Age-standardised rate of high-grade abnormalities per 1,000 women screened aged 20–69 years, states and territories, 2000 and 2001	28
Figure 8:	Age-standardised incidence rates for micro-invasive squamous cell cancer, women aged 20–69 years, Australia, 1989–2000	30
Figure 9:	Age-specific incidence rates of micro-invasive squamous cell cancer, women aged 20–69 years, Australia, 1999 and 2000	31
Figure 10:	Age-standardised incidence rates of cervical cancer, Australia, 1989-2000	32
Figure 11:	Age-specific incidence rates of cervical cancer, Australia, 1999 and 2000	33
Figure 12:	Age-standardised cervical cancer incidence rates by women aged 20–69 years, states and territories, 1996–1999 and 1997–2000	34
Figure 13:	Age-standardised incidence rates of cervical cancer by histological type, women aged 20–69 years, Australia, 1989–2000	35
Figure 14:	Age-standardised incidence rates of cervical cancer by location by women aged 20–69 years, Australia, 1993–1996 and 1997–2000	36
Figure 15:	Age-standardised death rates from cervical cancer, Australia, 1982-2001	40
Figure 16:	Age-specific cervical cancer death rates by age group, Australia, 1988–1991 and 1998–2001	41
Figure 17:	Age-standardised cervical cancer death rates by women aged 20–69 years, states and territories, 1994–1997 and 1998–2001	42
Figure 18:	Age-standardised cervical cancer death rates by location, women aged 20–69 years, 1994–1997 and 1998–2001	43
Figure 19:	Age-standardised cervical cancer mortality rates by Indigenous status, women aged 20–69 years (Qld, SA, SA and NT), 1996–1999, 1997–2000 and 1998–2001	45

Acknowledgments

Financial support by the Australian Government Department of Health and Ageing and assistance of the Cancer Screening Section in the department are gratefully acknowledged. The authors of this report are Ms Janet Markey, Dr Chris Stevenson and Mr John Harding from the Australian Institute of Health and Welfare. The authors wish to extend their gratitude to those people working in the National Cervical Screening Program who provided data and comments for this report. The authors also acknowledge the input of the members of the National Advisory Committee to the National Cervical Screening Program, and the Australasian Association of Cancer Registries. The support received during the production of this report from the staff at the AIHW Health Registers and Cancer Monitoring Unit is gratefully acknowledged.

National Cervical Screening Program

New South WalesSouth AustraliaMs Jayne RossMs Sue GilchristMr Hassan MamoonMs Penny IosifidisMs Liz Martin

Victoria Ms Valerie Gardner
Dr Heather Mitchell Mr Paul Chandler

Ms Cathy Burrows
Mr Rory Wilby

Australian Capital Territory
Ms Helen Sutherland

QueenslandMr Peter CouveeMs Jennifer MullerMs Coral SwanMr Stephen Heim

Mr Nathan Dunn

Northern Territory

Ms Karen Finch

Western Australia

Ms Sarah Steele

Ms Nerida Steel

Australian Government Department of Health
and Ageing, Cancer Screening Section

Ms Andriana Koukari Ms Liz Pugh

Summary

This report is the fifth national report on the performance of the National Cervical Screening Program in Australia. Cervical screening services are provided as part of mainstream health services with general practitioners performing approximately 80% of Pap smears. The program is funded by Medicare, the Australian Government, and the state and territory governments.

There is a set of performance monitoring indicators agreed to by the National Advisory Committee to the program. This report presents statistics on the monitoring undertaken. The main features of the report are summarised below.

Participation

- The total number of women who participated in cervical screening in 2000–2001 was 3,314,787 of whom 3,244,329 (98%) were in the screening program target age group of 20–69 years. This represented an increase of 16,621 in the number of women screened in 1999–2000.
- Between the periods 1999–2000 and 2000–2001 the proportion of women in the target population (women aged 20–69 years) participating in cervical screening declined from 62.6% to 61.8%.
- Participation in screening declined in all 5-year age groups within the target population between 1999–2000 and 2000–2001 except for the youngest (20–24) and oldest (65–69) age groups which each showed a slight increase. The largest decline was in women in their thirties decreasing from 67.0% to 64.9% for women aged 30–34 years and from 68.7% to 67.1% for women aged 35–39 years.

Early re-screening

• The recommended screening interval is 2 years following a negative smear. Of a cohort of women screened in February 2000 who had a negative Pap smear result, 32% screened again within 21 months. It is not known what proportion of this early re-screening is justified on clinical grounds.

Detection of abnormalities

- A low-grade abnormality includes atypia, warty atypia, possible cervical intraepithelial neoplasia (CIN), equivocal CIN, and CIN 1, and a high-grade abnormality is defined to include CIN 1/2, CIN 2 and CIN 3 or adenocarcinoma in situ. The ratio of histologically confirmed low-grade abnormalities to high-grade abnormalities was 1.3 for Australia in 2001, the same as in 2000. The 2001 ratio did not include data for the Northern Territory.
- In 2001, the National Cervical Screening Program detected 13,555 women in the target age group 20–69 years with high-grade abnormalities. The number of high-grade abnormalities was highest in the younger age groups. For women under 35 years of age, the rate of high-grade abnormalities was over 10 per 1,000 women screened whereas it was less than 2 per 1,000 women aged 50 years and over.

Incidence and mortality

- The number of new cases of cervical cancer in Australia has continued to decline. There were 745 new cases in Australia in 2000 compared with 1,072 detected in 1989.
- Cervical cancer is the 15th most common cause of cancer mortality in women, accounting for 262 deaths in 2001. Although there was some fluctuation from year to year, the age-standardised mortality rate from cervical cancer declined. For all women aged 20 years and over there was a decline of 5.9 per 100,000 women in 1982 to 2.8 per 100,000 in 2001. During the same period, for women in the target age group of 20–69 years the rate declined from 5.1 per 100,000 to 2.4 per 100,000. The mortality rate also declined for women aged 70 years and over from 2.7 per 100,000 in 1982 to 1.1 per 100,000 in 2001.
- Women in the target age group from remote locations experienced a relatively high mortality rate from cervical cancer 3.0 deaths per 100,000 compared with 2.3 deaths per 100,000 women in metropolitan areas. However, between the periods 1994–1997 and 1998–2001, the age-standardised cervical cancer mortality rate declined in all regions (metropolitan, rural and remote).
- Prior to 1998, only Western Australia, South Australia and the Northern Territory had Indigenous mortality registration data of sufficient quality to be publishable. In 1998, Queensland's coverage of Indigenous deaths reached an acceptable level to be included in the analysis of Indigenous mortality data. For these jurisdictions, in the period 1998–2001 there were 20 deaths from cervical cancer among Indigenous women in the target age group (an age-standardised mortality rate of 11.4 per 100,000 women). This is more than four times the corresponding rate in non-Indigenous women (2.5 per 100,000). Compared with the 1996–1999 mortality rate for Indigenous women in the target age group, which was 9.8 per 100,000, there was an increase in mortality in the 1998–2001 period. However, these rates are based on relatively small numbers of cases and may be subject to large variability. Despite the relatively large size of the apparent increase in the rate, it is still within the range of variation that would be expected due to chance.